Udforsk Servier
Servier, grundlagt i 1954, er den første selvstændige farmaceutiske gruppe. Vi har afdelinger i 149 lande med mere end 22.000 ansatte, hvoraf næsten 3.000 er indenfor forskning og udvikling
Coronavirus Information (COVID-19)
- 04/06/2020 - Servier completes the acquisition of Symphogen
- 20/05/2020 - Clinical Trials: Servier adapts to ensure continuity
- 19/05/2020 - Global warming: the Servier strategy validated by the SBTi
- 17/05/2020 - Servier is more committed than ever in the fight against hypertension
- 14/05/2020 - Phase 1 Results for ALLO-501 in Non-Hodgkin Lymphoma to be Presented at ASCO
- 06/05/2020 - Covid-19: Mécénat Servier sets up remote skills-based sponsorship missions
- 05/05/2020 - Golden Ticket 2020 awarded to Rgenta Therapeutics, a biotech specializing in diseases considered incurable
- 30/04/2020 - COVID-19: The “Health Innovation Coalition – Health Crisis” selects a new projects and the lengthens its call for projects until May 7th.
- 29/04/2020 - Final closing of the Kurma Biofund III fund
- 27/04/2020 - Mécénat Servier is mobilizing against school disengagement
- 21/04/2020 - Covid-19: The Health Innovation Coalition selects its first digital projects!
- 20/04/2020 - Servier, committed to helping those who fight against the Covid-19
- 14/04/2020 - COVID-19: Servier China on the digital innovation front
- 06/04/2020 - Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
- 02/04/2020 - World Autism Awareness Day: Servier is committed
- Read more news